Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.40 -4.1%	$1.75	$1.23 ▼ $3.78	$304.17M	0.99	5.09 million shs	1.27 million shs
ETON Eton Pharmaceuticals	$14.08 -0.8%	$14.38	$3.03 ▼ $18.41	$377.60M	1.34	287,707 shs	219,295 shs
OCX OncoCyte	$2.83 -3.7%	$3.02	$1.92 ▼ $4.75	$80.94M	0.97	75,791 shs	19,903 shs
TRML Tourmaline Bio	$14.52 -2.7%	$14.28	$11.56 ▼ $29.79	$372.95M	2.14	279,570 shs	259,481 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+2.10%	+7.35%	-24.74%	-21.93%	-58.87%
ETON Eton Pharmaceuticals	+3.43%	+23.71%	-8.92%	-0.77%	+340.68%
OCX OncoCyte	+3.16%	+6.91%	-21.39%	+33.64%	+16.21%
TRML Tourmaline Bio	+5.96%	+22.18%	-20.59%	-18.15%	-21.38%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.9671 of 5 stars	3.5	3.0	2.0	4.2	0.6
ETON Eton Pharmaceuticals	2.2549 of 5 stars	3.5	3.0	2.6	0.8	0.6
OCX OncoCyte	2.3974 of 5 stars	3.3	3.0	1.9	2.5	0.6
TRML Tourmaline Bio	2.5901 of 5 stars	3.5	3.0	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$9.29	563.49% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$27.67	96.50% Upside
OCX OncoCyte	2.67	Moderate Buy	$4.42	56.07% Upside
TRML Tourmaline Bio	3.00	Buy	$45.20	211.29% Upside

Current Analyst Ratings Breakdown

Latest OCX, TRML, ETON, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
3/28/2025	OCX OncoCyte	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$5.00
3/25/2025	OCX OncoCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$4.00 ➝ $4.00
3/25/2025	OCX OncoCyte	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.25 ➝ $4.25
3/19/2025	ALLO Allogene Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $8.00
3/19/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $26.00
3/19/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $24.00
3/19/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
3/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
3/14/2025	ALLO Allogene Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
3/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$5.00

(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	13,825.95	N/A	N/A	$3.04 per share	0.46
ETON Eton Pharmaceuticals	$39.01M	9.68	$0.00 per share	4,502.79	$0.60 per share	23.47
OCX OncoCyte	$1.88M	43.03	N/A	N/A	$2.48 per share	1.14
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.33	N/A	N/A	N/A	N/A	-52.13%	-41.29%	5/12/2025 (Estimated)
ETON Eton Pharmaceuticals	-$940K	-$0.15	N/A	28.16	N/A	-15.81%	-36.29%	-16.84%	5/8/2025 (Estimated)
OCX OncoCyte	-$27.78M	-$4.40	N/A	N/A	N/A	-6,122.29%	-269.32%	-59.71%	5/13/2025 (Estimated)
TRML Tourmaline Bio	-$42.12M	-$2.87	N/A	N/A	N/A	N/A	-20.97%	-20.56%	5/12/2025 (Estimated)

Latest OCX, TRML, ETON, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	$0.00 million	N/A
5/12/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.05	N/A	N/A	N/A	N/A	N/A
3/24/2025	Q4 2024	OCX OncoCyte	-$0.40	$0.48	+$0.88	-$1.93	$0.16 million	$1.49 million
3/18/2025	Q4 2024	ETON Eton Pharmaceuticals	-$0.02	-$0.02	N/A	-$0.02	$10.53 million	$11.65 million
3/13/2025	Q4 2024	ALLO Allogene Therapeutics	-$0.34	-$0.28	+$0.06	-$0.28	$0.01 million	N/A
3/13/2025	Q4 2024	TRML Tourmaline Bio	-$0.91	-$0.86	+$0.05	-$0.86	N/A	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCX OncoCyte	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
ETON Eton Pharmaceuticals	N/A	1.51	1.41
OCX OncoCyte	N/A	0.53	0.50
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ETON Eton Pharmaceuticals	27.86%
OCX OncoCyte	55.35%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	24.30%
ETON Eton Pharmaceuticals	14.89%
OCX OncoCyte	1.58%
TRML Tourmaline Bio	11.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	217.27 million	158.72 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.17 million	Optionable
OCX OncoCyte	120	28.60 million	17.18 million	No Data
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

OCX, TRML, ETON, and ALLO Headlines

Recent News About These Companies

American Century Companies Inc. Purchases New Stake in Tourmaline Bio, Inc. (NASDAQ:TRML)

April 14 at 3:12 AM | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Rating of "Buy" by Brokerages

April 12, 2025 | marketbeat.com

Tourmaline Bio price target lowered to $63 from $74 at Truist

April 11, 2025 | markets.businessinsider.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Rating of "Buy" by Analysts

April 10, 2025 | americanbankingnews.com

Polymer Capital Management HK LTD Acquires Shares of 79,400 Tourmaline Bio, Inc. (NASDAQ:TRML)

April 8, 2025 | marketbeat.com

Pictet Asset Management Holding SA Boosts Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML)

April 4, 2025 | marketbeat.com

Tourmaline Bio: We Should Wait For Upcoming Phase 2b Trial Data

April 3, 2025 | seekingalpha.com

Truist biotech analyst holds an analyst/industry conference call

April 2, 2025 | markets.businessinsider.com

Swiss National Bank Takes Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

March 31, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by Analysts

March 16, 2025 | marketbeat.com

TOURMALINE BIO Earnings Results: $TRML Reports Quarterly Earnings

March 15, 2025 | nasdaq.com

Tourmaline Bio (TRML) Gets a Buy from Wedbush

March 15, 2025 | markets.businessinsider.com

Tourmaline Bio price target raised to $43 from $42 at Wedbush

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 14, 2025 | finanznachrichten.de

Tourmaline Bio reports Q4 EPS (86c), consensus (87c)

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio shares fall as Q4 loss widens

March 14, 2025 | investing.com

Tourmaline Bio sees cash runway into 2H27

March 14, 2025 | markets.businessinsider.com

Tourmaline Bio’s 2024 Financial Results and Strategic Advances

March 14, 2025 | tipranks.com

Tourmaline Bio, Inc. Announces Over-Enrolled Phase 2 TRANQUILITY Trial and Strengthens Cardiovascular Scientific Advisory Board Amid Positive Financial Outlook

March 13, 2025 | quiverquant.com

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

March 13, 2025 | globenewswire.com

Piper Sandler Sticks to Their Buy Rating for Tourmaline Bio (TRML)

March 10, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCX, TRML, ETON, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.40 -0.06 (-4.11%)

As of 04:00 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Eton Pharmaceuticals NASDAQ:ETON

$14.08 -0.11 (-0.78%)

As of 04:00 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

OncoCyte NASDAQ:OCX

$2.83 -0.11 (-3.74%)

As of 04:00 PM Eastern

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Tourmaline Bio NASDAQ:TRML

$14.52 -0.41 (-2.75%)

As of 04:00 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time